Publication:
Increasing Therapy Related Myeloid Neoplasms in Multiple Myeloma

Simple item page
dc.contributor.authorFernández-Caballero, M
dc.contributor.authorSalmerón, D
dc.contributor.authorChen-Liang, TH
dc.contributor.authorHurtado, AM
dc.contributor.authorGarcía Malo, MD
dc.contributor.authorOrtuño, FJ
dc.contributor.authorRoldán, V
dc.contributor.authorVicente, V
dc.contributor.authorJerez, A
dc.contributor.authorDe Arriba, F
dc.contributor.authorChirlaque López, María Dolores
dc.contributor.departmentCiencias Sociosanitarias
dc.date.accessioned2024-01-12T11:45:26Z
dc.date.available2024-01-12T11:45:26Z
dc.date.issued2018-11-13
dc.description© 2018 Stichting European Society for Clinical Investigation Journal Foundation. This document is made available under the CC-BY-NC 4.0 license http://creativecommons.org/licenses/by-nc /4.0/ This document is the submitted version of a published work that appeared in final form in European Journal of Clinical Investigation.es
dc.description.abstractBackground: Despite the longer survival achieved in multiple myeloma (MM) patients due to new therapy strategies, a concern is emerging regarding an increased risk of secondary primary malignancies (SPMs) and how to characterize those patients at risk. We performed a retrospective study covering a 28‐year follow‐ up period (1991‐2018) in a tertiary single institution. Material and Methods: Data of 403 MM patients were recorded and compared with the epidemiologic register of the population area covered by our centre, calculating the standardize incidence ratio (SIR) for the different types of SPMs diagnosed in the MM cohort. Fine and Gray regression models were used to identify risk factors for SPMs. Results: Out of the 403 MM patients, 23 (5.7%) developed SPMs: 13 therapyrelated myeloid (TRM) malignancies (10 of them (77%) myelodysplastic syndrome (MDS), 1 acute lymphoid leukaemia and 9 solid neoplasms. In the MM cohort, the relative risk of MDS was significantly higher than in the general population. Survival of patients with TRM malignancies was poor with a median of 4 months from the diagnosis, and most of them showed complex karyotype. Within the MM subset, multivariable analysis showed a higher risk of TRM malignancies in patients that previously received prolonged treatment with lenalidomide (>18 months). Conclusions: Though the improvement in MM outcome during the last decades is an unprecedented achievement, it has been accompanied by the rise in TRM malignancies with complex cytogenetic profile and poor prognosis that are in the need of an improved biologic and therapeutic approach.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.identifier.citationEuropean Journal of Clinical InvestigationVolume 49, Issue 2 e13050
dc.identifier.doihttps://doi.org/10.1111/eci.13050
dc.identifier.issnElectronic: 1365-2362
dc.identifier.issnPrint: 0014-2972
dc.identifier.urihttp://hdl.handle.net/10201/137251
dc.languageenges
dc.publisherWileyes
dc.relationSin financiación externa a la Universidades
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/eci.13050es
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectComplex karyotypees
dc.subjectMultiple myelomaes
dc.subjectMyelodysplastic syndromees
dc.titleIncreasing Therapy Related Myeloid Neoplasms in Multiple Myelomaes
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
relation.isAuthorOfPublicationd574b2ee-b5f0-4552-b9e9-a7622381f3f6
relation.isAuthorOfPublication.latestForDiscoveryd574b2ee-b5f0-4552-b9e9-a7622381f3f6
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
SegundaNeo_2019_deposito.pdf
Size:
174.2 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos